Resultaterne af en befolkningsfarmakokinetik analyse af disse forsøg har vist at pædiatriske patienter med en legemesvægt ≤40 kg har en reduceret systemisk eksponering (målt ved Css) af A771726 i forhold til voksne patienter med rheumatoid artrit (se afsnit 4. 2).
The results of a population pharmacokinetic analysis of these trials have demonstrated that pediatric patients with body weights ≤ 40 kg have a reduced systemic exposure (measured by Css) of A771726 relative to adult rheumatoid arthritis patients (see section 4.2).